This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer and other malignancies of the head and neck undergoing radiation therapy and/or receiving systemic therapy before surgery. An hpMRI is like a standard MRI but involves the use of an imaging contrast agent called hyperpolarized 13-C-pyruvate. Diagnostic procedures, such as hpMRI, may predict a patient's response to treatment and may help plan the best treatment.
Be willing and able to provide informed consent
Be informed of the investigational nature of this study
Be diagnosed with thyroid cancer and other malignancies of the head and neck with intent for treatment
Have a history of severe claustrophobia
Have electrically, magnetically or mechanically activated implants that would preclude magnetic resonance imaging (MRI)
Have a history of cardiac arrhythmia
Have an allergy to Gadavist intravenous contrast
M.D. Anderson Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator